BMY vs MRK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BMY · Bristol-Myers Squibb$62.14 ▼ 1.57%
MRK · Merck & Co$146.73 ▼ 0.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BMY +35.9%
- MRK +73.1%
Head to head
| Metric | BMY | MRK |
|---|---|---|
| Price | $62.14 | $146.73 |
| Change today | ▼ 1.57% | ▼ 0.14% |
| Market cap | $127.02B | $361.73B |
| Return, 3 months | -4.2% | +12.1% |
| Return, year to date | +19.1% | +41.4% |
| Return, 1 year | +37.6% | +74.0% |
| P/E (TTM) | 13.8 | 148.2 |
| P/B | 5.4 | 8.1 |
| P/E percentile vs own 5y | 37th | 95th |
| Dividend yield | 4.06% | 2.32% |
| Revenue growth (YoY, latest qtr) | +6.9% | +4.7% |
| Net profit growth (YoY) | -1.5% | -12.4% |
| Gross margin | 69.2% | 71.8% |
| Operating margin | 29.2% | 9.2% |
| Net margin | 18.5% | 3.6% |
| Return on equity | 44.1% | – |
| Analyst target vs. price | +8.2% | +14.1% |
| Analyst buy share | 44% | 79% |
| RSI (14) | 51 | 51 |
| 30-day volatility | 34.5% | 33.2% |
| Max drawdown, 1 year | -16.8% | -11.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRK is the largest of the group by market value.
- MRK has returned the most over the past year.
- BMY carries the lowest trailing P/E.
- BMY pays the highest dividend yield.
- BMY is growing revenue fastest.
- BMY keeps the most profit per dollar of sales.
- MRK has been the calmest stock over the last 30 days.